[{"countryName":"Worldwide","languageLinks":[{"languageName":"English","languageUrl":"/en.html"}]},{"countryName":"USA","languageLinks":[{"languageName":"English","languageUrl":"/en-us.html"}]},{"countryName":"Japan","languageLinks":[{"languageName":"Japanese","languageUrl":"/jp/ja.html"}]}]
The link you have selected will take you outside of the Roche Sequencing USA website.
Combining more than a decade of probe design experience with a high-fidelity probe manufacturing process, the KAPA HyperCap Heredity Panel enables comprehensive, in-depth access to hereditary disease genomic content. This compact panel for hybridization-based target enrichment offers greater sequencing efficiency, high on-target rates, and low PCR duplication rates. Order this 10 Mb hybrid capture panel today and start investigating heredity disease tomorrow.
- Enrich for 3332 genes strongly associated with hereditary genetic diseases and oncology, including ClinVar pathogenic and likely pathogenic variants
- Maximize sequencing efficiency with >98% target coverage at 30X with (10 M high-quality clusters)
- Streamline targeted sequencing with the HyperCap Workflow v3, driven by KAPA HyperPrep or KAPA HyperPlus Library Prep Kits
Maximize sequencing efficiency with >98% target coverage at 30X with 10 M high-quality clusters
- Enrich for more than 85% of ClinVar pathogenic and likely pathogenic content at >30X by targeting 3332 carefully selected genes with a sequencing-efficient 10 Mb capture panel
- Achieve a high percentage of bases covered at ≥30X for disease-associated genes from key genomic databases
Figure 2. Key sequencing metrics generated with the KAPA HyperCap Heredity Panel. Target-enriched libraries were created following the standard KAPA HyperCap Workflow v3 with the KAPA HyperPlus Kit, using 100 ng of gDNA as input (duplicate samples using gDNA from 16 Coriell cell lines) and 8-plex pre-capture multiplexing. Final libraries were sequenced on a NovaSeq™ 6000 system (2 x 100 bp) and downsampled to 10 M high-quality filtered clusters prior to analysis.
